| Description: |
The recently approved drug vemurafenib (Zelboraf) has been hailed as a breakthrough in the treatment of melanoma, the deadliest form of skin cancer. But roughly one-quarter of patients who take the medication develop a troublesome side effect: secondary skin cancers called squamous cell carcinomas. Now, a new study identifies the specific genetic mechanism that causes this side effect. [Source: USA Today]
|
 |
